| P2093 | author name string | Nabila Noor | |
| | Howard A. Rockman | |
| | Chetan B. Patel | |
| P2860 | cites work | Functional Selectivity and Classical Concepts of Quantitative Pharmacology | Q22242288 |
| | The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor | Q22253381 |
| | Functional specialization of beta-arrestin interactions revealed by proteomic analysis | Q24318455 |
| | Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2 | Q24532154 |
| | Transduction of receptor signals by beta-arrestins | Q28246395 |
| | G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization | Q28276743 |
| | Independent beta-arrestin2 and Gq/protein kinase Czeta pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor | Q28572837 |
| | {beta}-Arrestin-2 Mediates Anti-apoptotic Signaling through Regulation of BAD Phosphorylation | Q28577649 |
| | Regulation of carbamoyl phosphate synthetase by MAP kinase | Q28578262 |
| | beta-arrestin-biased agonism at the beta2-adrenergic receptor | Q40034384 |
| | Monitoring agonist-promoted conformational changes of beta-arrestin in living cells by intramolecular BRET. | Q40110003 |
| | G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer | Q40281519 |
| | Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy | Q40298849 |
| | Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. | Q40626751 |
| | Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. | Q41080173 |
| | Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases | Q41175767 |
| | Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts | Q41714300 |
| | beta-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress | Q41917803 |
| | The Role of a Conserved Region of the Second Intracellular Loop in AT1 Angiotensin Receptor Activation and Signaling | Q42441168 |
| | Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling | Q42453523 |
| | Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK. | Q42800979 |
| | Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling | Q42804681 |
| | Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor | Q43586918 |
| | Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure | Q44528608 |
| | β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure | Q44591642 |
| | PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching | Q45069283 |
| | Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol | Q46048377 |
| | Structure and conformational changes in the C-terminal domain of the beta2-adrenoceptor: insights from fluorescence resonance energy transfer studies | Q46260678 |
| | Effects of AGTR1 A1166C gene polymorphism in patients with heart failure treated with candesartan | Q46507308 |
| | The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation | Q50335944 |
| | Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death. | Q51094115 |
| | The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. | Q53021334 |
| | The Angiotensin II Type 1 Receptor Gene Polymorphism Is Associated With Coronary Artery Vasoconstriction | Q57606076 |
| | Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet | Q74316955 |
| | Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome | Q81272805 |
| | Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury | Q82828304 |
| | Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 |
| | Beta-arrestins and cell signaling | Q29616793 |
| | Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. | Q30476292 |
| | Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol | Q30478644 |
| | Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes | Q33181618 |
| | Genetic deletion of p90 ribosomal S6 kinase 2 alters patterns of 5-hydroxytryptamine 2A serotonin receptor functional selectivity | Q33714695 |
| | Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling | Q33819399 |
| | beta-Arrestin-dependent activation of Ca(2+)/calmodulin kinase II after beta(1)-adrenergic receptor stimulation | Q33840022 |
| | Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery | Q33890786 |
| | Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group | Q33893139 |
| | Inverse, protean, and ligand-selective agonism: matters of receptor conformation | Q33938998 |
| | Teaching old receptors new tricks: biasing seven-transmembrane receptors | Q33985759 |
| | Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). | Q34093722 |
| | Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists | Q34122067 |
| | Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study | Q34155432 |
| | Principles: receptor theory in pharmacology | Q34310931 |
| | Seven-transmembrane-spanning receptors and heart function | Q34503394 |
| | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol | Q34522261 |
| | Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. | Q34536660 |
| | Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor | Q34548751 |
| | beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor | Q34562493 |
| | Integrating signals from RTKs to ERK/MAPK. | Q34627656 |
| | Beta-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes | Q35133773 |
| | Ligand-selective receptor conformations revisited: the promise and the problem | Q35181787 |
| | Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. | Q35951476 |
| | A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling | Q36082162 |
| | New concepts in drug discovery: collateral efficacy and permissive antagonism | Q36303814 |
| | Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. | Q36786816 |
| | The evasive nature of drug efficacy: implications for drug discovery | Q36894549 |
| | Mitogenic signaling pathways induced by G protein-coupled receptors | Q36929839 |
| | Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. | Q36936400 |
| | A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure | Q37000342 |
| | Role of endocytosis in the activation of the extracellular signal-regulated kinase cascade by sequestering and nonsequestering G protein-coupled receptors. | Q37105461 |
| | '7TM receptor allostery: putting numbers to shapeshifting proteins | Q37591623 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | membrane protein | Q423042 |
| | hormone | Q11364 |
| | peptide | Q172847 |
| | angiotensin receptor | Q2504907 |
| | nerve tissue protein | Q6996861 |
| | signal transduction | Q828130 |
| | cell surface receptor | Q2476074 |
| P304 | page(s) | 983-992 | |
| P577 | publication date | 2010-09-20 | |
| | 2010-12-01 | |
| P1433 | published in | Molecular Pharmacology | Q1943386 |
| P1476 | title | Functional selectivity in adrenergic and angiotensin signaling systems | |
| | Functional Selectivity in Adrenergic and Angiotensin Signaling Systems | |
| P478 | volume | 78 | |